Work

Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.5063

Authors: G. Attard, T. A. Yap, A. H. Reid, C. Parker, M. Barrett, F. Raynaud, M. Dowsett, D. Dearnaley, G. Lee, J. S. De Bono

Institutions: Institute of Cancer Research, Royal Marsden Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3009079267

Cites:

Cited by: 18

Related to: 10